Published in final edited form as:

Bioorg Med Chem Lett. 2008 February 1; 18(3): 1031–1036. doi:10.1016/j.bmcl.2007.12.028.

Potent Memapsin 2 (β -Secretase) Inhibitors: Design, Synthesis, Protein-Ligand X-ray Structure and *in vivo* Evaluation

Arun K. Ghosh^a, Nagaswamy Kumaragurubaran^a, Lin Hong^{b,c}, Sarang Kulkarni^a, Xiaoming Xu^a, Heather B. Miller^a, Dandepally Srinivasa Reddy^a, Vajira Weerasena^c, Robert Turner^c, Wanpin Chang^c, Gerald Koelsch^{b,c}, and Jordan Tang^{c,d}

^a Departments of Chemistry and Medicinal Chemistry, Purdue University, West Lafayette, IN 47907

^b CoMentis Inc, Oklahoma City, OK 73104

^c Protein Studies Program, Oklahoma Medical Research Foundation, University of Oklahoma Health Science Center, Oklahoma City, OK 73104

^d Department of Biochemistry and Molecular Biology, University of Oklahoma Health Science Center, Oklahoma City, OK 73104

Abstract

Structure-based design, synthesis and biological evaluation of a series of peptidomimetic β -secretase inhibitors incorporating hydroxyethylamine isosteres are described. We have identified inhibitor **24** which has shown exceedingly potent activity in memapsin 2 enzyme inhibitory (K_i 1.8 nM) and cellular (IC_{50} = 1 nM in Chinese hamster cells) assays. Inhibitor **24** has also shown very impressive *in vivo* properties (up to 65% reduction of plasma A β) in transgenic mice. The X-ray structure of protein-ligand complexes of memapsin 2 revealed critical interactions in the memapsin 2 active site.

Keywords

Alzheimer; design; synthesis; inhibitor; memapsin 2; secretase

Memapsin 2 (β -secretase, BACE 1) has become a major target for the development of inhibitor drugs for the treatment of Alzheimer's Disease (AD).¹ Memapsin 2 is the first protease that cleaves β -amyloid precursor protein (APP) in the pathway leading to the generation of amyloid- β peptide (A β) in the brain.^{2,3} The excess level of A β results in the formation of amyloid plaques and neurofibrillary tangles. The neurotoxicity of A β ultimately leads to neuronal death, brain inflammation, dementia and AD.⁴ Consequently, inhibition of memapsin 2 has emerged as an excellent therapeutic target for the intervention of AD. On the basis of initial kinetics and substrate specificity information, we designed a number of potent inhibitors incorporating a nonhydrolyzable Leu-Ala hydroxyethylene dipeptide isostere.^{5, 6} One of the early key inhibitors was OM99-2 (**1**; Figure 1). It has shown potent inhibitory activity (K_i = 1.6 nM) for human memapsin 2.^{6a} An X-ray crystal structure of **1**-bound memapsin 2 provided critical molecular insight and drug-design templates for the memapsin 2 active site.⁷ Based upon the crystallographic information and preliminary structure-activity relationship studies, we then designed a number of highly potent and selective inhibitors.⁸ Inhibitor **2** incorporating

methylsulfonyl alanine as the P₁-ligand and oxazolymethyl urethane as the P₃-ligand exhibited excellent potency ($K_i = 0.12$ nM against memapsin 2) and selectivity over BACE-2 (3800-fold) and cathepsin D (2500-fold).⁸ However, its cellular inhibitory potency was in the low micromolar range (IC₅₀ of 1.4 μ M) in Chinese hamster ovary cells.

To further improve inhibitor properties, we subsequently developed inhibitors incorporating substituted isophthalamides as P₂–P₃ ligands in combination with the Leu-Ala hydroxyethylene dipeptide isostere.⁹ As shown in Figure 1, inhibitor **3** has exhibited excellent memapsin 2 inhibitory potency ($K_i = 1.1$ nM), good cellular inhibitory activity (IC₅₀ = 39 nM) and has shown a 30% reduction of A β ₄₀ production in transgenic mice after a single intraperitoneal administration (8 mg/kg).⁹ In our continuing effort to further improve inhibitor properties, we have also investigated inhibitors incorporating a variety of other isosteres. Recently, a number of reports incorporating isophthalamide-based P₂-ligands in memapsin 2 inhibitor design have appeared in the literature.¹⁰ Herein, we now report the design and synthesis of a series of potent memapsin 2 inhibitors incorporating a substituted isophthalamide as P₂–P₃ ligands in combination with hydroxyethylamine dipeptide isosteres. A number of inhibitors have displayed excellent memapsin 2 inhibitory potency. We have identified an inhibitor (**24**) which has shown excellent enzyme and cellular inhibitory activity, good selectivity over BACE-2 and cathepsin D, and excellent *in vivo* properties in transgenic mice. A high resolution protein-ligand X-ray structure of this inhibitor also provided important molecular insight into ligand binding-site interactions for further molecular design.

The synthesis of substituted hydroxyethylamine isosteres is shown in Scheme 1. Reactions of amines **4–8** with known¹¹ epoxides **9** and **10** in isopropanol at reflux provided the respective aminoalcohol. Exposure of the resulting aminoalcohol to trifluoroacetic acid (20% in CH₂Cl₂) at 23 °C for 2 h removed the BOC-group and afforded the corresponding diamines **11–16** in excellent yields (80–85%) in a two step sequence. The synthesis of various inhibitors containing the hydroxyethylamine isosteres are shown in Scheme 2. Substituted aminoisophthalamide derivatives **17–20** were prepared as described previously.^{9,10} Coupling of these acids with various amines **11–16** using EDC/HOBt in the presence of *i*-Pr₂NEt furnished respective inhibitors (**21–29**) in 45–55% yields. For synthesis of inhibitor **31**, the requisite acid **30** was prepared by *m*-CPBA oxidation of the corresponding known sulfide.⁸ Coupling of acid **30** with amine **14** as described above afforded inhibitor **31** (47% yield).

Structure and inhibitory potency of various inhibitors are shown in Table 1. The memapsin 2 inhibitory activity of various inhibitors was determined using established assay protocols described previously.¹² As it can be seen, size and substituents on the hydroxyethylamine isosteres are important for potency. Inhibitors with a (*R*)- α -methylbenzyl isophthalamide derivative as the P₂–P₃ ligand and a valine-derived P₂'-ligand (**21**) exhibited modest enzyme inhibitory activity (entry 1). An unsubstituted indolymethyl group as the P₂'-ligand has shown a K_i value of 230 nM and a cellular IC₅₀ value of 620 nM in Chinese hamster ovary cells.¹³ In an effort to promote interaction with the residues in the S₂'-subsite, we incorporated a *N*-methylsulfonamide functionality on the indole nitrogen. The corresponding inhibitor **23** has shown a significant improvement in memapsin 2 inhibitory activity ($K_i = 27$ nM) and cellular activity (IC₅₀ = 200 nM) compared to inhibitor **22**. Incorporation of a 3-methoxybenzyl derivative as the P₂'-ligand provided a very potent inhibitor **24** (GRL-8234). It exhibited a K_i value of 1.8 nM, thus a 15-fold potency enhancement over the indole derivative **23**. Furthermore, inhibitor **24** has shown a very impressive cellular memapsin 2 inhibitory activity with an average IC₅₀ value of 1 nM (5 determinations). Inhibitor **25** with a P₃-(*S*)- α -methylbenzylamide is notably less potent than inhibitor **24** with a P₃-(*R*)-isomer. Inhibitor **26** with a P₁-leucine side chain has shown significant reduction in potency, thus indicating the preference for a more sterically demanding P₁-phenylmethyl substituent. The lipophilic 3-methoxybenzyl P₂'-ligand is very critical for the enhanced cellular inhibitory properties of

inhibitor **24**. As can be seen, replacement of this P₂'-ligand with an isopropyl group resulted in inhibitor **27** ($K_i = 425$ nM; $IC_{50} = 1.1$ μ M) with a significant reduction of potency. In particular, there is a 1000-fold reduction in cellular inhibitory activity compared to **24**. P₃-oxazolymethyl amide derivatives (compounds **28** and **29**) have shown only moderate activity compared to α -methylbenzyl derivative **24**. Compound **31** with a methylsulfonyl alanine as the P₂-ligand along with a oxazolymethyl urethane as the P₃-ligand (entry 10) exhibited no appreciable activity. This is in marked contrast to inhibitor **2** with a hydroxyethylene isostere.⁸

Inhibitor selectivity over other aspartyl proteases may be important, particularly over memapsin 1 (BACE 2) and cathepsin D. Memapsin 1 has specificity similar to memapsin 2 and it is presumed to have important physiological functions.¹⁴ Cathepsin D is also important as it is involved in cellular protein catabolism.¹⁵ We have evaluated the selectivity properties of inhibitor **24** against recombinant memapsin 1 and human cathepsin D. It is more than 39-fold selective over memapsin 1 and more than 23-fold selective over cathepsin D. It exhibited an encouraging IC_{50} value against CYP3A4 (696 nM).

We examined the *in vivo* efficacy to inhibit A β production in transgenic mice by inhibitor GRL-8234. The compound was injected intraperitoneally to Tg2576 mice¹⁶ and the plasma was sampled immediately prior to and 3 hours post-administration. Treatment with compound **24** resulted in a 65% reduction of A β_{40} in plasma at 3 h after a single administration of 8 mg/kg (Figure 2). Some of the decrease is likely originated from the reduction of A β the brain since the production of A β in young Tg2576 mice is almost entirely produced in the brain¹⁷ then transferred to the plasma. Also, the plasma A β has been shown to correlate well with brain A β in memapsin 2 inhibition using Tg2576 mice.^{13,18} The inhibition of memapsin 2 activity *in vivo* was significant compared to the relative A β_{40} in vehicle-treated control animals collected at 3 h post-administration ($p=0.000012$) and relative to the baseline A β_{40} levels for the treated group ($p=0.0072$). As observed for compound **3**⁹ and the prototype inhibitor OM003-DR₉,¹³ the plasma reduction by GRL-8234 was of a magnitude that indicates inhibition in brain A β_{40} production in Tg2576 mice of this age. Inhibition of brain A β_{40} by 15–20% at 2 h post administration of a single 4 mg/kg dose was confirmed, and further studies in rats indicate robust brain penetration of GRL-8234. The details of this investigation will be published elsewhere.

To obtain molecular insight into the binding properties of inhibitor **24**, we determined the protein-ligand X-ray structure of **24**-bound memapsin 2.¹⁹ As shown in Figure 3, the transition-state hydroxyl group forms two hydrogen bonds (2.4 and 3.3 Å bond distances) with the active site aspartic acid residue Asp32. The hydroxyethylamine nitrogen forms another tight hydrogen bond with catalytic residue Asp228 (2.6 Å bond distance). The P₃-phenyl ring occupies a unique position which spans S₃- and S₄-subsites and causes a significant positional shift of the protein loop containing residues from 8 to 13 (the 10's loop) located in the S₃/S₄ pocket. This conformational change to accommodate the bound inhibitor identifies a flexible part of the active site cleft which can be further exploited for ligand design. This binding pocket consists of residues 12-14, 229-232, and 335. These residues make direct contact with the phenyl ring at P₃. The P₂-sulfonamide fits well into the S₂ pocket and makes extensive interactions with memapsin 2. One of the sulfonamide oxygen atoms is within hydrogen bonding distance with the Asn233 side chain nitrogen and the Ser325 side chain oxygen (3.3 and 3.2 Å bond distance respectively). The same sulfonamide oxygen also makes ionic interactions with the guanidine side chain of Arg235, which is believed to confer selectivity of GRL-8234 over Cathepsin D, an important human aspartic protease which has a valine at this position. The Arg235 side chain appeared to be quite flexible and adopted a different conformation than our previously reported structures.^{7,9} The other sulfonamide oxygen makes hydrogen bonds to Thr232 and Asn233 main chain nitrogen atoms at 3.3 and 2.9 Å bond distances respectively. The terminal methoxybenzene makes non-polar interactions with residues in the hydrophobic P₂' binding-

site which includes Gly34, Ile126, Tyr198 and the flap residues Pro70, Tyr71 and Thr72. This may explain its enhanced binding affinity over indole **22** or indolesulfonamide derivative **23**.

In summary, we have investigated various structural elements of memapsin 2 inhibitors containing hydroxyethylamine dipeptide isosteres and substituted isophthalamides as P₂–P₃ ligands. These research efforts have resulted in inhibitors with improved potency and cellular inhibitory properties compared to inhibitors with hydroxyethylene isosteres. Inhibitor **24** has shown excellent enzyme inhibitory activity as well as cellular inhibitory potency in Chinese hamster ovary cells. It has also exhibited very impressive *in vivo* properties. An intraperitoneal administration of inhibitor **24** to Tg2576 mice resulted in a 65% reduction of A β ₄₀ production at 3 h after a single dose of 8 mg/kg. A protein-ligand X-ray crystal structure of **24**-bound memapsin 2 has provided important molecular insight into the ligand-binding site interactions. This information has provided the basis for further design and improvement of inhibitor properties that are currently in progress.

Acknowledgements

Financial support by the National Institutes of Health (AG 18933) is gratefully acknowledged.

References and Notes

- (a) Ghosh AK, Nagaswamy K, Tang J. *Curr Med Chem* 2005;16:1609. (b) Baxter EW, Reitz AB. *Annu Rep Med Chem* 2005;40:35.
- (a) Lin X, Koelsch G, Wu S, Downs D, Dashti A, Tang J. *Proc Natl Acad Sci, USA* 2000;97:1456. [PubMed: 10677483] (b) Vassar R, Bennett BD, Babu-Khan S, Khan S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, Fisher S, Fuller J, Edenson S, Lile J, Jarosinski MA, Biere AL, Curran E, Burgess T, Louis JC, Collins F, Treanor J, Rogers G, Citron M. *Science* 1999;286:735. [PubMed: 10531052] and references cited therein
- (a) Sinha S, Lieberburg I. *Proc Natl Acad Sci USA* 1999;96:11049. [PubMed: 10500121] (b) Potter H, Dressler D. *Nature* 2000;18:125.
- (a) Selkoe DJ. *Nature* 1999;399A:23. (b) Selkoe D. *Physiol Rev* 2001;81:741. [PubMed: 11274343]
- (a) Ermolieff J, Loy JA, Koelsch G, Tang J. *Biochemistry* 2000;39:12450. [PubMed: 11015226] (b) Turner RT III, Koelsch G, Hong L, Castanheira P, Ghosh AK, Tang J. *Biochemistry* 2001;40:10002.
- (a) Ghosh AK, Shin D, Downs D, Koelsch G, Lin X, Ermolieff J, Tang J. *J Am Chem Soc* 2000;122:3522. (b) Ghosh AK, Bilcer G, Harwood C, Kawahama R, Shin D, Hussain KA, Hong L, Loy JA, Nguyen C, Koelsch G, Ermolieff J, Tang J. *J Med Chem* 2001;44:2865. [PubMed: 11520194] (c) Ghosh AK, Devasamudram T, Hong L, DeZutter C, Xu X, Weerasena V, Koelsch G, Bilcer G, Tang J. *Bioorg Med Chem Lett* 2005;15:15. [PubMed: 15582402]
- Hong L, Koelsch G, Lin X, Wu S, Terzyan S, Ghosh AK, Zhang XC, Tang J. *Science* 2000;290:150. [PubMed: 11021803]
- Ghosh AK, Kumaragurubaran N, Hong L, Lei H, Hussain KA, Liu C, Devasamudram T, Weerasena V, Turner R, Koelsch G, Bilcer G, Tang J. *J Am Chem Soc* 2006;128:5310. [PubMed: 16620080]
- Ghosh AK, Kumaragurubaran N, Hong L, Kulkarni S, Weerasena V, Turner R, Koelsch G, Bilcer G, Tang J. *J Med Chem* 2007;50:2399. [PubMed: 17432843]
- (a) Maillard MC, Hom RK, Benson TE, Moon JB, Mamo S, Bienkowski M, Tomasselli AG, Woods DD, Prince DB, Paddock DJ, Emmons TL, Tucker JA, Dappen MS, Brogley L, Thorsett ED, Jewett N, Sinha S, John V. *J Med Chem* 2007;50:776. [PubMed: 17300163] (b) Stachel SJ, Coburn CA, Steele TG, Jones KG, Loutzenhiser EF, Gregro AR, Rajapakse HA, Lai Ming-Tain, Crouthamel M-C, Xu M, Tugusheva K, Lineberger JE, Pietrak BL, Espeseth AS, Shi X-P, Chen-Dodson E, Holloway MK, Munshi S, Simon AJ, Kuo L, Vacca JP. *J Med Chem* 2004;47:6447. [PubMed: 15588077] and references cited therein
- (a) Beaulieu P, Wernic D, Duceppe JS, Guindon Y. *Tetraheron Lett* 1995;36:3317. (b) Rotella DP. *Tetraheron Lett* 1995;36:5453.

12. Memapsin 2 inhibition was measured using recombinant enzyme produced from *E. coli* expression as described in ref. 2a. A fluorogenic substrate Arg-Glu(EDANS)-Glu-Val-Asn-Leu-Asp-Ala-Glu-Phe-Lys (Dabcyl)-Arg was used with 0.47 μ M of the enzyme in 0.1 M Na-acetate + 5% dimethylsulfoxide, pH 4.5 at 37 °C. The excitation wavelength was 350 nm and the emission wavelength was 490 nm.
13. Chang WP, Koelsch G, Wong S, Downs D, Da H, Weerasena V, Gordon B, Devasamudram T, Bilcer G, Ghosh AK, Tang J. *J Neurochem* 2004;89:1409. [PubMed: 15189343]
14. Turner RT, Loy JA, Nguyen C, Devasamudram T, Ghosh AK, Koelsch G, Tang J. *Biochemistry* 2002;41:8742. [PubMed: 12093293]
15. Diment S, Leech MS, Stahl PD. *J Biol Chem* 1988;263:6901. [PubMed: 3360812]
16. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. *Science* 1996;274:99. [PubMed: 8810256]
17. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. *J Neurosci* 2001;21:372. [PubMed: 11160418]
18. Chang WP, Downs D, Huang XP, Da H, Fung KM, Tang J. *FESAB J* 2007;21:3184.
19. The protein-ligand X-ray structure of 24-bound memapsin 2 has been deposited in PDB (PDB ID: 2vkm). Recombinant human BACE was expressed and purified as previously described. Crystals of free BACE (APO form) were grown using a hanging drop vapor diffusion method. Monoclinic crystals suitable for structure determination were obtained at 13 % PEG 8000, pH 6.5 and 17 °C with a protein concentration of 18 mg/ml. The crystals grow to full size (about 0.25 mm $\times$ 0.35 mm $\times$ 0.05 mm) in 4–5 weeks. Inhibitor 24-memapsin 2 complex crystal was prepared by soaking the free memapsin 2 crystal in concentrated inhibitor solution for two days. Memapsin 2/inhibitor crystal was soaked in the mother liquor plus 20% (v/v) glycerol and quickly frozen under a cryogenic nitrogen gas stream. Cryogenic diffraction data from a single crystal was recorded on a Mar 345 image plate mounted on a MSC-Rigaku RU-300 X-ray generator. The structure was determined by molecular replacement implemented with the program AmoRe using the previously determined memapsin 2 structure (PDB ID: 1M4H) as a search model.²⁰ Rotation and translation functions followed by the rigid-body refinement with data from 15 Å to 3.5 Å resolution in space group P21 gave unambiguous solutions for the four memapsin 2 molecules in the asymmetric unit. A random selection of 8% of reflections was set aside as the test set for cross-validation during the refinement. The refined model has well defined electron density for the inhibitor and its corresponding structure was built into the active site. The four molecules in the crystallographic asymmetric unit have essentially identical structures. The crystal form was determined to be monoclinic with a resolution of 2.05 Å. The unit cell parameters are a=86.7 Å, b=130.3 Å, c=87.7 Å, β =97.4°.
20. Hong L, Turner RT, Koelsch G, Shin D, Ghosh AK, Tang J. *Biochemistry* 2002;41:10963. [PubMed: 12206667]

Figure 1.
Structure of memapsin 2 inhibitors **1-3**

Figure 2. Inhibitor **24** (GRL-8234) reduced Aβ₄₀ production following a single intraperitoneal administration at 8 mg/kg. Plasma Aβ₄₀ assessed at 3 hours post-injection was significantly lower than control group ($p=0.0072$). Error bars are s.e.m. from $n=5$ animals per group

Figure 3.
Stereoview of the X-ray Crystal structure of **24** (thick stick with gray carbon) with memapsin 2. Hydrogen bonds between the inhibitor and memapsin 2 are shown in white dotted lines.

Scheme 1.
Synthesis of hydroxyethylamine substituted isosteres

Scheme 2.
Synthesis of memapsin 2 inhibitors

Structures and potencies of Memapsin 2 inhibitors.

Bioorg Med Chem Lett. Author manuscript; available in PMC 2009 February 1.

Entry	Inhibitor structure	Cmpd. number	K_i (nM, Memapsin 2)	Cellular IC_{50} (μ M)
8.		28	552	nd
9.		29	894	nd
10.		31	15000	nd